Proteases as prognostic markers in cancer

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 613-618

  Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; METALLOPROTEINASE; PROTEINASE; TUMOR MARKER; UROKINASE;

CANCER; HUMAN; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; CATHEPSIN B; CATHEPSIN D; CATHEPSINS; COLLAGENASES; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030002073     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Duffy, M. J. Role of proteolytic enzymes in cancer invasion and metastasis. Clin. & Exp. Metastasis, 10: 145-155, 1992.
2. Aznavoonan, S., Murphy, A. N , Stetler-Stevenson, W. G., and Liotta, L. Molecular aspects of tumor cell invasion and metastasis. Cancer (Phila.), 71: 1368-1383, 1993.
3. Schmitt, M., Janicke, F., and Graeff, H. Tumor associated proteases. Fibrinolysls, 6 (Suppl. 4). 3-26, 1992.
4. Duffy, M. J. Do proteases play a role in cancer invasion and metastasis? Eur. J. Cancer Clin. Oncol., 23: 583-589, 1987.
5. Duffy, M. J. Urokinase plasminogen activator and malignancy. Fibrinolysis, 7: 295-302, 1993.
6. Mars, W., Zarnegar, R., and Michalopoulos, G. K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol., 143: 949-958, 1993.
7. Odekon, L. E., Sato, Y., Rifkin, D. B. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell. Physiol.. 150: 258-263, 1992.
8. Binder, B R. Influence of urokinase on cell proliferation and invasion. Blood Coagul. Fibrinolysis. 1: 717-720, 1990
9. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H J. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Preliminary report. Cancer (Phila.), 62: 531-533, 1988.
10. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990
11. Janicke, F., Schmitt, M., Hafter, R., Holrieder, A., Babic, R., Ulm, K., Gossner, W., and Graeff, H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-78, 1990.
12. Schmitt, M., Janicke, F., and Graeff, H. Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul. Fibrinolysis, 1: 695-702, 1990.
13. Spyratos, F., Martin, P-M., Hacene, K., Romain, S., Andneu, C., Ferrero-Pous, M., Deytieux, S., Le Doussal, V., Tubiana-Hulin, M., and Brunet, M. Multiparametnc prognostic evaluation of biological factors in primary breast cancer. J. Natl. Cancer. Inst., 84: 1266-1272, 1992.
14. Cook, D., Mahmoud-Alexandroni, N., Gaffney, P. J., and Burnand, K. G. Plasminogen activators are powerful indicators of prognosis in human breast cancer. Br. J. Surg., 78: 1495, 1991.
15. Foekens, J. S., Schmitt, M., Pache, L., Van Putton, W., Peters, H. A., Bontenbal, M., Janicke, F., and Klijn, J. G. M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52: 6101-6105, 1992.
16. Ferno, M., Borg, A., Killander, D., Hirschberg, L., and Brundell, J. Urokinase plasminogen activator as prognostic factor in breast cancer: measured with a novel immunoluminometric assay suited for routine use. Breast Cancer Res Treat., 32: 30, 1994
17. Grondahl-Hansen, J., Chnstensen, I. J., Rosenquist, C., Brunner, N., Mouridsen, H. T., Dano, K., and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53: 2513-2521, 1993.
18. Kute, T., Grondahl-Hansen, J., Russell, G., Christensen, I. J., and Brunner, N. Urokinase-type plasminogen activator, its inhibitor and cathspsin D predicts prognosis in node negative breast cancer. Proc. Am. Assoc., Cancer Res., 35: 201, 1994.
19. Duffy, M. J., Reilly, D., Nugent, A., McDermott, E , Faul, C., Fennelly, J. J., and O'Higgins, N. Evaluation of proteolytic enzymes implicated in cancer metastasis as prognostic markers in breast cancer. Eur. J. Surg. Oncol., 18 (Suppl. 1). 21, 1992.
20. Janicke, F., Schmitt, M., Pache, L., Ulm, K, Harbeck, N., Hofler, H., and Graeff, H. Urokinase plasminogen activator (uPA) and its inhibitor PAI-1 are strong and independent prognostic factor in node-negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
21. Duffy, M. J., Reilly, D., Nugent, A., McDermott, E., Faul, C., Fennelly, J. J., and O'Higgins, N. Evaluation of proteolytic enzymes implicated in cancer metastasis as prognostic markers in breast cancer. Ir. J. Med. Sci., 161 (Suppl. 11 ): 49, 1992.
22. Duffy, M. J., Reilly, D., McDermott, E., O'Higgins, N., Fennelly, J. J., and Andreasen, P. A. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer (Phila.), 74: 2276-2280, 1994.
23. Janicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A., and Graeff, H. Both the cytolols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res., 54: 2527-2530, 1994.
24. Nykjaer, A., Petersen, C. M., Moller, B., Jensen, P. H., Moestrup, S. K., Holtet, T. L., Etzerodt, M., Thogersen, H. C., Munch, M., Andreasen, P., and Gliemann, J, Purified alpha-2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator type-1 complex. Evidence that the alpha-2-macrogiobulin receptor mediates cellular degradation of the urokinase receptor bound complexes. J. Biol. Chem., 207: 14543-14546, 1992.
25. Nekarda, H., Siewert, J., Schmitt, M., and Ulm, K. Tumor-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet, 343: 117, 1994.
26. Ganesh, S., Sier, C. F. M., Grifftoen, G., Vloedgraven, H., De Boer, A., Welvaart, K., van de Velde, C., van Krieken, J., Verheijen, J., Lamers, C., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
27. Skelly, M. M., Mulcahy, H. E., Connell, T., Troy, A., Duggan, C., Duffy, M. J., Sheahan, K., and O'Donoghue, D. P. Urokinase-type plasminogen activator (u-PA) is independently related to outcome in colorectal cancer. Ir. J. Med. Sci., 164 (Suppl. 14). 2, 1995.
28. Mulcahy, H. E., Duffy, M. J., Gibbons, P., McCarthy, P., Parfrey, N. A., O'Donoghue, D. P. and Sheahan, K. Urokinase-type plasminogen activator and outcome in Duke's B colorectal cancer. Lancet. 344: 583-584, 1994.
29. Hasui, Y., Marutsuka, K., Suzumiya, J., Kitada, S., Osada, Y., and Sumiyoshi, A. The content of urokinase-type plasminogen activator as a prognostic factor in bladder cancer. Int. J. Cancer. 50: 871-873, 1992.
30. Oka, T., Ishida, T., Nishino, T., and Sugimachi, K. Immunohistochemical evidence of urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma. Cancer Res., 57: 3522-3525, 1991
31. Kobayashi, H., Fujishiro, S., and Terao, T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res., 54: 6539-6548, 1994.
32. Kuhn, W., Pache, L., Schmalfeldt, S., Dettmar, P., Schmitt, M., Janicke, F., and Graeff, H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum based chemotherapy Gynecol. Oncol, 55: 401-409, 1994.
33. Clarke, G. M. Do we really need prognostic factors for breast cancer. Breast Cancer Res. Treat, 30: 117-126, 1994.
34. Janicke, F., Thomssen, C. Pache, M., Schmitt, M., and Graeff, H. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: M. Schmitt, H. Graeff, and G. Kindermann (eds.), Prospects in Diagnosis and Treatment of Breast Cancer, pp. 207-218. Amsterdam: Excerpta Medica. 1994.
35. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res , 48: 1348-1349, 1988.
36. Ryan, T. J., Seeger, J. I., Kumar, S. A., and Dickerman, H. W. Estradiol preferentially enhances extracellular tissue plasminogen activator of MCF-7 breast cancer cells. J. Biol. Chem., 259: 14324-14327, 1984.
37. Duffy, M. J., O'Grady, P., Simon, J., Rose, M., and Lijnen, H. R. Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. J. Natl. Cancer Inst., 77: 621-623, 1986.
38. Westley, B., and Rochefort, H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell, 20: 352-362, 1980.
39. Vignon, F., Capony, F., Chambon, M., Freiss, G., Garcia, M., and Rochefort, H. Autocrine growth stimulation on the MCF7 breast cancer cells by the estrogen-regulated 52K protein. Endocrinology, 118: 1537-1545, 1986.
40. r 52,000 cathepsin D secreted by breast cancer cells. Cancer Res., 48: 3688-3692, 1988.
41. Rochefort, H., Capony, F., and Garcia, M. Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev. 9: 321-331, 1990.
42. r 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res., 49: 6008-6014, 1989.
43. Spyratos, F., Brouillet, J. P., Defrenne, A., Hacene, K., Rouesse, J., Maudelonde, T., Brunet, M., Andrieu, C., Desplaces, A., and Rochefort, H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer Lancet. 2: 1115-1118, 1989.
44. Tandon, A. K., Clarke, G. M., Chamness, G. C., Chirgwin, J., and McGuire, W. L. Cathepsin D and prognosis in breast cancer. N. Engl. J. Med., 322: 297-302, 1990.
45. Rochefort, H., Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur. J. Cancer, 28A: 1780-1783, 1992.
46. Kute, T. E., Shao, Z-M., Sugg, K., Long, R. T., Russell, G. B., and Case, L. D. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res., 52: 1-6, 1992.
47. Foekens, J. A., van Putten, W. L. J., Portengen, H., de Koning, H., Thirion, B., Alexieva-Figusch, J., and Klijn, J. C. M. Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J. Clin. Oncol., 11: 899-908, 1993.
48. Duffy, M. J., Reilly, D., Brouillet, J. P., McDermott, E., Faul, C., O'Higgins, N., Fennelly, J. J., Maudelonde, T., and Rochefort, H. Cathepsin D concentrations in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin. Chem., 38: 2114-2116, 1992.
49. Pujol, P., Maudelonde, T., Daures, J. P., Rovanet, P., Brouillet, J. P., Pujol, H., and Rocheford, H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer (Phila.), 71: 2006-2012, 1993.
50. Henry, J. A., McCarthy, A. L., Angus, B., Westley, B. R., May, F., Nicholson, S., Cairns, J., Harris, A. L., and Home, C. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer (Phila.), 65: 265-271, 1990.
51. Isola, S., Weitz, S., Visakorpi, T., Holli, K., Shea, R., Khabbaz, N., and Kallioniemi, O-P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J. Clin. Oncol., 11: 36-43, 1993.
52. Domagala, W., Striker, G., Szadowska, A., Dukowicz, A., Weber, K., and Osborn, M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry, no correlation with survival at 5 years. Am. J. Pathol., 141: 1003-1012, 1992.
53. 0 breast carcinoma. Am. J. Surg. Pathol., 18: 158-166, 1994.
54. Bevilacqua, P., Boracchi, P., and Gasparini, G. Prognostic indicators for early-stage breast carcinoma. Int. J. Oncol., 5: 559-564, 1994.
55. Ravdin, P. M., Tandon, A. K., Allred, D. C., Clark, G. M., Fuqua, S. A. W., Hilsenbeck, S. H., Chamness, G. C., and Osborne, C. K. Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J. Clin. Oncol., 12: 467-474, 1994.
56. Joensuu, H., Toikkanen, S., and Isola, J. Stromal cell cathepsin D expression and long term survival in breast cancer. Br. J. Cancer, 71: 155-159, 1995.
57. Ferno, M., Baldetorp, B., Borg, A., Brouillet, J. P., Olsson, H , Rochefort, H., Sellberg, G., Sigurdsson, H., Killander, D., for the South Sweden Breast Cancer Group. Cathepsin D. both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur. J. Cancer, 30A: 2042-2048, 1994.
58. Benraad, T. J., Geurts-Moespot, A., Sala, M., Piffanelli, A., Ross, A., and Foekens, J. A. Quality control of cathepsin-D measurement by the EORTC receptor study group. Eur. J. Cancer. 28: 72-75, 1992.
59. Sloane, B. F., Moin, K., and Lah, T. T. Regulation of lysosomal endopeptidases in malignant neoplasia. in: G. Pretlow and H. Pretlow (eds.), Biochemical and Molecular Aspects of Selected Cancers, Vol. 2, pp. 411-466. New York: Academic Press, 1994.
60. Nishimura, Y., Furono, K., and Kato, K. Biosynthesis and processing of lysosomal cathepsin L in primary cultures of rat hepatocytes. Arch. Biochem. Biophys., 263: 107-116, 1988.
61. Hara, K., Kominami, E., and Katunuma, N. Effect of proteinase inhibitors on intracellular processing of cathepsin B, H, and L in rat macrophages. FEBS Lett., 231: 229-231, 1988.
62. Simon, J. M., and Duffy, M. J. Distribution, characterization and clinical significance of a cathepsin B-like enzyme in breast cancer. Biochem. Soc. Trans., 16: 192, 1988.
63. Lah, T. T., Kokalj-Kunovar, M., Strukelj, B., Pungercar, J., Barlic-Maganja, D., Drobnic-Kosorok, M,. Kastelic, L., Babnik, J., Golouh, R., and Turk, V. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer, 50: 36-44, 1992.
64. Thomssen, C., Schmitt, M., Goretzki, L., Oppelt, P., Pache, L., Dettmar, P., Janicke, F., and Graeff, H. Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin. Cancer Res., 1: 741-746, 1995.
65. Visscher, D. W., Sloane, B. F., Sameni, M., Babiarz, J. W., Jacobson, J., and Crissman, J. D. Clinicopathologic significance of cathepsin B immunostaining in transitional neoplasia. Mod. Pathol., 7: 76-81, 1994.
66. Campo, E., Munoz, J., Miquel, R., Palacin, A., Cardesa, A., Sloane, B. F., and Emmert-Buck, M. R. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am. J. Pathol., 145: 301-309, 1994.
67. Inoue, T., Ishida, T., Sugio, K., and Sugimachi, K. Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res., 54: 6133-6136, 1994.
68. Sukoh, N., Abe, S., Ogura, S., Isobe, H., Takekawa, H., Inoue, K., and Kawakami, Y. Immunohistochemical study of cathepsin B, prognostic significance in human lung cancer. Cancer (Phila.), 74: 46-51, 1994
69. Tschesche, H., Blaser, J., Kleine, T., Bode, W., Reinemer, P., Grams, F., Schnierer, S., Thomssen, C., Schmitt, M., Pache, L., Janicke, F., and Graeff, H. Structure and function of matrix metalloproteinases and their significance in breast cancer. In. M. Schmitt, H. Graeff, and G. Kindermann (eds.), Prospects in Diagnosis and Treatment of Breast Cancer, pp. 77-88. Amsterdam: Excerpts Medica, 1994.
70. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagwa, A., Yamamoto, E., and Seiki, M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (Lond.), 370: 61-65, 1994.
71. Daidone, M. G., Silvestrini, R., D'Errico, A., Di Fronzo, G., Benini, E., Mancini, A. M., Garbisa, S., Liotta, L. A., and Grigioni, W. F. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int. J. Cancer, 48: 529-532, 1991.
72. Visscher, D. W., Hoyhtya, M., Ottosen, S. K., Liang, C-M., Sarkar, F. H., Crissman, J. D., and Fndman, R. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer, 59: 339-344, 1994.
73. Engel, G., Heselmeyer, K., Auer, G., Backdahl, M., Eriksson, E., and Linder, S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int. J. Cancer, 58: 830-835, 1994.